PharmEnable

PharmEnable is a Cambridge (UK)-based biotechnology company that develops next-generation small molecule drugs, focusing on novelty, diversity, and three-dimensionality. The company’s interdisciplinary approach combines advanced medicinal chemistry expertise with cutting-edge artificial intelligence/computational methods to provide new treatments for diseases with high clinical demand. PharmEnable's proprietary drug discovery platform provides strong momentum for generating novel chemical entities targeting challenging targets. It models drug targets to identify key molecular interactions and maps and expands new chemical space that can modulate specific targets. Advanced medicinal chemistry expertise guides the development of synthesizable, complex, and three-dimensional small molecules, enhancing specificity and reducing off-target effects. Its vision is to replicate the specificity of biologics in robust and scalable small molecule forms. PharmEnable's mission is to deliver life-changing medicines. Its world-class team works across a range of disease areas where drug specificity is a significant challenge, such as cancer and neurological disorders.